Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free JBIO Stock Alerts

Jade Biosciences (JBIO) Financials

Jade Biosciences logo
$25.26 +0.74 (+3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$25.30 +0.04 (+0.16%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Jade Biosciences

Annual Income Statements for Jade Biosciences

This table shows Jade Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.61 -23 -52 -76 -70 -127
Consolidated Net Income / (Loss)		 -19 -23 -103 -76 -70 -127
Net Income / (Loss) Continuing Operations		 -9.61 -23 -103 -76 -70 -127
Total Pre-Tax Income 		-9.61 -23 -51 -75 -70 -127
Total Operating Income		 -8.89 -23 -53 -81 -75 -114
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.89 23 106 81 75 114
Selling, General & Admin Expense		 0.95 8.04 15 17 21 20
Research & Development Expense		 7.94 15 39 64 53 93
Total Other Income / (Expense), net		 -0.72 0.12 3.50 5.94 5.02 -14
Interest & Investment Income		 -0.08 0.07 1.83 5.95 5.04 7.78
Other Income / (Expense), net		 -0.65 0.06 1.67 - - -22
Income Tax Expense		 0.00 0.00 0.03 0.06 0.06 0.06
Basic Earnings per Share		 ($40.31) ($1.87) ($2.10) ($2.87) ($2.44) ($3,196.49)
Weighted Average Basic Shares Outstanding		 242.23K 12.29M 24.47M 26.33M 28.58M 31.37M
Diluted Earnings per Share		 ($40.31) ($1.87) ($2.10) ($2.87) ($2.44) ($3,196.49)
Weighted Average Diluted Shares Outstanding		 242.23K 12.29M 24.47M 26.33M 28.58M 31.37M
Weighted Average Basic & Diluted Shares Outstanding		 242.23K 12.29M 24.81M 27.86M 28.99M 49.32M

Quarterly Income Statements for Jade Biosciences

This table shows Jade Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -19 -20 -20 -23 -25 -16 -5.43 -2.52 -32 -25 -68
Consolidated Net Income / (Loss)		 -19 -20 -20 -23 -25 -16 -5.43 -2.52 -32 -25 -68
Net Income / (Loss) Continuing Operations		 -19 -20 -20 -23 -25 -16 -5.43 -2.52 -32 -25 -68
Total Pre-Tax Income 		-19 -20 -20 -23 -25 -16 -5.38 -2.52 -32 -25 -68
Total Operating Income		 -20 -21 -22 -25 -26 -15 -6.40 -3.39 -28 -27 -55
Total Operating Expenses		 20 21 22 25 26 15 6.40 3.39 28 27 55
Selling, General & Admin Expense		 4.30 4.48 4.25 4.54 4.92 1.38 4.87 3.39 5.23 5.39 6.41
Research & Development Expense		 16 17 18 20 21 14 1.53 0.00 23 22 49
Total Other Income / (Expense), net		 1.31 1.81 1.71 1.43 1.39 -1.31 1.03 0.87 -4.36 2.23 -13
Interest & Investment Income		 1.31 1.80 1.71 1.44 1.40 0.39 1.03 0.87 1.83 2.25 2.83
Basic Earnings per Share		 ($0.76) ($0.71) ($0.73) ($0.83) ($0.86) ($5.16) ($0.19) ($0.09) ($0.86) ($0.48) ($2.15)
Weighted Average Basic Shares Outstanding		 25.17M 27.64M 26.33M 27.80M 28.76M 3.16M 28.58M 28.99M 28.43M 39.58M 31.37M
Diluted Earnings per Share		 ($0.76) ($0.71) ($0.73) ($0.83) ($0.86) ($5.16) ($0.19) ($0.09) ($0.86) ($0.48) ($2.15)
Weighted Average Diluted Shares Outstanding		 25.17M 27.64M 26.33M 27.80M 28.76M 3.16M 28.58M 28.99M 28.43M 39.58M 31.37M
Basic & Diluted Earnings per Share		 - - - - - - - - - - ($2.15)
Weighted Average Basic & Diluted Shares Outstanding		 27.65M 27.67M 27.86M 28.81M 28.87M 28.87M 28.99M 28.99M 32.63M 46.00M 49.32M

Annual Cash Flow Statements for Jade Biosciences

This table details how cash moves in and out of Jade Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.06 50 -32 1.09 10 19
Net Cash From Operating Activities		 -7.86 -27 -39 -57 -71 -95
Net Cash From Continuing Operating Activities		 -7.86 -27 -39 -57 -71 -95
Net Income / (Loss) Continuing Operations		 -9.61 -23 -52 -76 -70 -127
Consolidated Net Income / (Loss)		 -9.61 -23 -52 -76 -70 -127
Depreciation Expense		 0.00 0.02 0.07 0.10 0.28 0.03
Amortization Expense		 0.00 0.02 -0.91 -3.06 -2.25 -0.78
Non-Cash Adjustments To Reconcile Net Income		 0.78 2.04 5.48 12 12 42
Changes in Operating Assets and Liabilities, net		 0.97 -6.51 7.76 9.82 -11 -8.24
Net Cash From Investing Activities		 0.00 -113 6.93 12 56 -247
Net Cash From Continuing Investing Activities		 0.00 -113 6.93 12 56 -247
Purchase of Property, Plant & Equipment		 0.00 -0.18 -0.20 -0.14 0.00 -0.20
Purchase of Investments		 0.00 -113 -148 -124 -20 -261
Sale and/or Maturity of Investments		 - 0.00 155 136 76 14
Other Investing Activities, net		 - - - - - -0.03
Net Cash From Financing Activities		 8.92 190 0.40 46 25 361
Net Cash From Continuing Financing Activities		 8.92 190 0.40 46 25 361
Repayment of Debt		 - - - - - 189
Issuance of Debt		 2.50 - - - - 0.00
Issuance of Common Equity		 0.00 127 0.15 45 24 171
Other Financing Activities, net		 0.01 0.00 0.62 0.99 1.48 0.24
Other Net Changes in Cash		 - - - - - -0.02

Quarterly Cash Flow Statements for Jade Biosciences

This table details how cash moves in and out of Jade Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 34 -29 -8.69 -14 22 0.05 2.64 10 141 -171 38
Net Cash From Operating Activities		 -15 -16 -15 -24 -20 -16 -11 -2.38 -37 -22 -34
Net Cash From Continuing Operating Activities		 -15 -16 -15 -24 -20 -16 -11 -2.38 -37 -22 -34
Net Income / (Loss) Continuing Operations		 -19 -20 -20 -23 -25 -16 -5.43 -2.52 -68 -25 -32
Consolidated Net Income / (Loss)		 -19 -20 -20 -23 -25 -16 -5.43 -2.52 -68 -25 -32
Depreciation Expense		 0.02 0.03 0.03 0.03 0.03 0.22 0.01 0.00 0.00 0.01 0.01
Amortization Expense		 -0.64 -0.81 -0.94 -0.76 -0.69 -0.46 -0.34 -0.23 - - -0.61
Non-Cash Adjustments To Reconcile Net Income		 3.03 3.24 3.23 4.19 3.88 2.00 1.50 1.19 27 4.10 9.64
Changes in Operating Assets and Liabilities, net		 1.67 1.50 3.30 -3.94 1.13 -1.57 -6.79 -0.83 4.23 -0.72 -11
Net Cash From Investing Activities		 3.98 -13 5.65 8.83 18 16 13 13 -13 -149 -98
Net Cash From Continuing Investing Activities		 3.98 -13 5.65 8.83 18 16 13 13 -13 -149 -98
Purchase of Property, Plant & Equipment		 -0.03 -0.03 -0.06 - - - - - - -0.06 -0.00
Purchase of Investments		 -33 -48 -28 -15 - -4.93 - 0.00 - - -113
Other Investing Activities, net		 - - - - - - - - - - 0.03
Net Cash From Financing Activities		 45 0.02 0.46 0.47 24 0.02 0.55 0.00 191 - 170
Net Cash From Continuing Financing Activities		 45 0.02 0.46 0.47 24 0.02 0.55 0.00 191 -0.16 170
Repayment of Debt		 - - - - - - - - - - -1.34
Other Financing Activities, net		 0.33 0.10 0.34 0.70 0.51 0.02 0.25 0.00 0.16 -0.16 0.24
Other Net Changes in Cash		 - - - - - - - - - - -0.02

Annual Balance Sheets for Jade Biosciences

This table presents Jade Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 4.72 175 135 127 73 350
Total Current Assets		 4.68 174 131 124 70 349
Cash & Equivalents		 4.57 54 22 23 69 88
Short-Term Investments		 - 113 107 99 0.00 248
Prepaid Expenses		 0.10 6.96 2.28 1.79 0.27 13
Plant, Property, & Equipment, net		 0.04 0.19 0.24 0.29 0.00 0.17
Total Noncurrent Assets		 0.00 0.84 3.56 2.90 3.15 0.80
Other Noncurrent Operating Assets		 0.00 0.84 3.56 2.90 3.15 0.80
Total Liabilities & Shareholders' Equity		 4.72 175 135 127 73 350
Total Liabilities		 1.77 2.95 8.56 18 120 17
Total Current Liabilities		 1.77 2.55 7.78 18 12 17
Accounts Payable		 0.62 1.21 2.58 2.40 1.29 2.15
Accrued Expenses		 1.16 1.15 4.82 15 9.63 14
Other Current Liabilities		 0.00 0.19 0.39 0.42 1.08 0.00
Total Noncurrent Liabilities		 0.00 0.40 0.78 0.33 108 0.72
Long-Term Debt		 - - - - 108 0.00
Other Noncurrent Operating Liabilities		 0.00 0.40 0.78 0.33 0.00 0.72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 16 - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 -13 172 127 109 -47 333
Total Preferred & Common Equity		 -13 172 127 109 -47 333
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -13 172 127 109 -47 333
Common Stock		 0.06 209 215 273 0.18 507
Retained Earnings		 -13 -36 -88 -163 -47 -174
Accumulated Other Comprehensive Income / (Loss)		 - -0.06 -0.47 0.24 0.00 0.13

Quarterly Balance Sheets for Jade Biosciences

This table presents Jade Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 156 141 107 112 91 78 224 202
Total Current Assets		 152 138 103 111 91 77 223 201
Cash & Equivalents		 61 32 9.12 31 31 44 221 50
Short-Term Investments		 89 103 90 73 58 32 - 149
Prepaid Expenses		 2.37 2.40 3.91 6.56 1.88 1.16 2.04 2.46
Plant, Property, & Equipment, net		 0.25 0.32 0.26 0.23 0.01 0.00 0.15 0.18
Total Noncurrent Assets		 3.04 2.96 3.32 0.70 0.34 0.16 0.84 0.91
Other Noncurrent Operating Assets		 3.04 2.96 3.32 0.70 0.34 0.16 0.84 0.91
Total Liabilities & Shareholders' Equity		 156 141 107 112 91 78 224 202
Total Liabilities		 14 15 16 17 10 2.49 22 23
Total Current Liabilities		 13 15 16 17 10 2.42 22 22
Accounts Payable		 5.53 3.50 3.31 4.18 0.91 0.07 7.59 1.35
Accrued Expenses		 7.38 11 12 12 8.95 2.04 10 16
Other Current Liabilities		 0.38 0.45 0.45 0.48 0.46 0.31 3.56 4.95
Total Noncurrent Liabilities		 0.55 0.43 0.40 0.28 0.15 0.07 0.79 0.75
Long-Term Debt		 - - - - - - 0.00 0.00
Other Noncurrent Operating Liabilities		 0.55 0.43 0.40 0.28 0.15 0.07 0.79 0.75
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 142 126 91 94 80 75 202 179
Total Preferred & Common Equity		 142 126 91 94 80 75 202 179
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 142 126 91 94 80 75 202 179
Common Stock		 266 269 278 306 308 311 319 322
Retained Earnings		 -123 -143 -187 -211 -228 -236 -117 -142
Accumulated Other Comprehensive Income / (Loss)		 -0.22 -0.20 -0.03 -0.08 0.22 0.05 -0.02 0.03

Annual Metrics And Ratios for Jade Biosciences

This table displays calculated financial ratios and metrics derived from Jade Biosciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 24,410,393.00 24,605,073.00 27,668,887.00 - 46,004,205.00
DEI Adjusted Shares Outstanding		 0.00 697,440.00 703,002.00 790,540.00 - 46,004,205.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -32.92 -73.85 -95.53 - -2.77
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -6.22 -16 -37 -57 -52 -79
Return On Investment Capital (ROIC_SIMPLE)		 - - - -52.06% -68.32% -23.90%
Earnings before Interest and Taxes (EBIT)		 -9.54 -23 -52 -81 -75 -135
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.54 -23 -52 -84 -77 -136
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -23 -30 -46 -63 -78
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.63 5.04 -2.48 -13 -2.19 -3.64
Increase / (Decrease) in Invested Capital		 0.00 6.68 -7.52 -11 11 -1.45
Book Value per Share		 ($55.09) $7.06 $5.15 $3.96 $2.65 $7.23
Tangible Book Value per Share		 ($55.09) $7.06 $5.15 $3.96 $2.65 $7.23
Total Capital		 2.94 172 127 109 76 333
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.57 -167 -129 -122 -79 -336
Capital Expenditures (CapEx)		 0.00 0.18 0.20 0.14 0.00 0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.67 4.41 -5.51 -16 -2.33 -3.88
Debt-free Net Working Capital (DFNWC)		 2.90 172 124 107 76 332
Net Working Capital (NWC)		 2.90 172 124 107 76 332
Net Nonoperating Expense (NNE)		 13 6.85 66 19 17 48
Net Nonoperating Obligations (NNO)		 -4.57 -167 -129 -122 -79 -336
Total Depreciation and Amortization (D&A)		 0.00 0.03 -0.84 -2.96 -1.97 -0.76
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.87) ($2.10) ($2.87) ($2.44) ($3,196.49)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 24.41M 24.47M 26.33M 28.58M 31.37M
Adjusted Diluted Earnings per Share		 $0.00 ($1.87) ($2.10) ($2.87) ($2.44) ($3,196.49)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 24.41M 24.47M 26.33M 28.58M 31.37M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.87) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 12.29M 24.81M 27.86M 28.99M 49.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.22 -16 -37 -57 -52 -79
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Jade Biosciences

This table displays calculated financial ratios and metrics derived from Jade Biosciences' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 24,923,874.00 27,649,226.00 27,668,887.00 27,862,961.00 28,808,334.00 28,867,711.00 - - 28,985,019.00 32,626,730.00 46,004,205.00
DEI Adjusted Shares Outstanding		 712,111.00 789,978.00 790,540.00 796,085.00 823,095.00 824,792.00 - - 828,143.00 32,626,730.00 46,004,205.00
DEI Earnings Per Adjusted Shares Outstanding		 -26.72 -24.79 -25.79 -29.13 -30.10 -19.73 - - -38.80 -0.77 -1.47
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -14 -15 -15 -17 -18 -10 -4.48 -2.37 -19 -19 -38
Return On Investment Capital (ROIC_SIMPLE)		 - - -14.11% -18.96% - -13.01% -5.86% -3.16% -9.65% -10.69% -11.57%
Earnings before Interest and Taxes (EBIT)		 -20 -21 -22 -25 -26 -17 -6.40 -3.39 -34 -27 -55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -22 -23 -25 -27 -17 -6.73 -3.61 -34 -27 -56
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.00 -8.92 -4.94 -15 -17 -12 -15 -9.64 -9.86 -7.86 -37
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.17 -9.48 -13 -8.43 -9.80 -8.24 -2.19 -1.16 -19 -20 -3.64
Increase / (Decrease) in Invested Capital		 -7.24 -6.04 -11 -2.60 -1.63 1.24 11 7.27 -9.58 -11 -1.45
Book Value per Share		 $5.69 $4.55 $3.96 $3.26 $3.28 $2.79 $2.65 $2.59 $6.95 $5.50 $7.23
Tangible Book Value per Share		 $5.69 $4.55 $3.96 $3.26 $3.28 $2.79 $2.65 $2.59 $6.95 $5.50 $7.23
Total Capital		 142 126 109 91 94 80 76 75 202 179 333
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -150 -135 -122 -99 -104 -89 -79 -76 -221 -199 -336
Capital Expenditures (CapEx)		 0.03 0.03 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -12 -16 -12 -10 -8.44 -2.33 -1.25 -20 -20 -3.88
Debt-free Net Working Capital (DFNWC)		 139 123 107 88 94 80 76 75 201 179 332
Net Working Capital (NWC)		 139 123 107 88 94 80 76 75 201 179 332
Net Nonoperating Expense (NNE)		 4.79 4.61 4.97 5.95 6.46 5.80 0.95 0.15 13 5.99 29
Net Nonoperating Obligations (NNO)		 -150 -135 -122 -99 -104 -89 -79 -76 -221 -199 -336
Total Depreciation and Amortization (D&A)		 -0.62 -0.78 -0.91 -0.73 -0.66 -0.24 -0.33 -0.22 0.00 0.01 -0.60
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.76) ($0.71) ($0.73) ($0.83) ($0.86) ($19.60) ($0.19) ($0.09) ($0.86) ($0.48) ($2.15)
Adjusted Weighted Average Basic Shares Outstanding		 25.17M 27.64M 26.33M 27.80M 28.76M 824.67K 28.58M 28.99M 28.43M 39.58M 31.37M
Adjusted Diluted Earnings per Share		 ($0.76) ($0.71) ($0.73) ($0.83) ($0.86) ($19.60) ($0.19) ($0.09) ($0.86) ($0.48) ($2.15)
Adjusted Weighted Average Diluted Shares Outstanding		 25.17M 27.64M 26.33M 27.80M 28.76M 824.67K 28.58M 28.99M 28.43M 39.58M 31.37M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($2.15)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.65M 27.67M 27.86M 28.81M 28.87M 824.99K 28.99M 28.99M 32.63M 46.00M 49.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -15 -15 -17 -18 -10 -4.48 -2.37 -19 -19 -38
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from JBIO's quarterly statements over the last few years, focusing on cash flow, profitability, and balance-sheet liquidity.

  • Significant financing inflows in 2025 boosted liquidity: net cash from financing activities was about $190.6 million in Q2 2025 and about $170.2 million in Q4 2025, helping fund operations while the business remains pre-revenue.
  • No long-term debt in the latest periods reduces leverage risk: Long-Term Debt sits at $0 in the recent Q2–Q3 2025 balance sheets.
  • Strong near-term liquidity at mid-2025: cash and cash equivalents around $221 million in Q2 2025 provide runway to support ongoing R&D and operations.
  • Revenue generation remains effectively zero: total revenue consistently reported as $0 across 2024–2025 quarters, indicating no product sales to date.
  • Ongoing equity dilution risk: there have been common equity issuances (e.g., late-2024) that expand the share base and could dilute existing holders.
  • Investing activity has been a cash outflow in several periods: sizable purchases of investments in multiple quarters (e.g., large outflows in Q3 2025 and Q4 2025) reducing cash from investing.
  • Persistent quarterly net losses: examples include large negative net income in several quarters (e.g., Q4 2025 around -$67.6m; Q2 2025 around -$67.8m; Q3 2025 around -$25.2m; Q1 2025 around -$2.5m).
  • Operating cash flow remains negative in most quarters: net cash from operating activities shows meaningful burn (e.g., Q4 2025 about -$33.6m; Q2 2025 about -$36.5m; Q3 2025 about -$22.0m; Q1 2025 around -$2.4m).
  • Significant negative retained earnings, signaling accumulated losses: large negative retained earnings (e.g., roughly -$142m in 2025 Q4; substantial negatives in earlier periods) reflect ongoing losses against equity.
  • Dilution pressure alongside negative earnings could add headwind for shareholders: sustained equity financings combined with losses may pressurize the stock’s value if the capital is not deployed into revenue-generating activities.
05/05/26 09:20 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Jade Biosciences' Financials

When does Jade Biosciences' financial year end?

According to the most recent income statement we have on file, Jade Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Jade Biosciences' net income changed over the last 5 years?

Jade Biosciences' net income appears to be on an upward trend, with a most recent value of -$127.41 million in 2025, rising from -$19.22 million in 2020. The previous period was -$69.63 million in 2024. Check out Jade Biosciences' forecast to explore projected trends and price targets.

What is Jade Biosciences' operating income?
Jade Biosciences' total operating income in 2025 was -$113.54 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $113.54 million
How has Jade Biosciences' revenue changed over the last 5 years?

Over the last 5 years, Jade Biosciences' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

How much debt does Jade Biosciences have?

Jade Biosciences' total liabilities were at $17.26 million at the end of 2025, a 85.6% decrease from 2024, and a 873.1% increase since 2020.

How much cash does Jade Biosciences have?

In the past 5 years, Jade Biosciences' cash and equivalents has ranged from $4.57 million in 2020 to $88.44 million in 2025, and is currently $88.44 million as of their latest financial filing in 2025.

How has Jade Biosciences' book value per share changed over the last 5 years?

Over the last 5 years, Jade Biosciences' book value per share changed from -55.09 in 2020 to 7.23 in 2025, a change of -113.1%.


Related Companies

Financial statements for NASDAQ:JBIO last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel